摘要
目的探究胸腺五肽联合四联抗结核方案治疗耐药性肺结核病的临床效果。方法选择2016年9月至2019年9月收治的60例耐药性肺结核患者为研究对象,根据治疗方法不同将其分为对照组和研究组,每组30例。对照组采用四联抗结核疗法治疗,研究组在对照组的基础上联合胸腺五肽注射液治疗。比较两组患者的临床疗效、肺功能指标、免疫功能指标及血清炎症因子水平。结果研究组患者的治疗总有效率为93.33%,显著高于对照组的70.00%,差异具有统计学意义(P<0.05)。治疗后,两组患者的FEV1%、FEV1/FVC均升高,且研究组高于对照组,差异具有统计学意义(P<0.05)。治疗后,两组患者的CD3+、CD4+、CD4+/CD8+均升高,且研究组高于对照组,差异具有统计学意义(P<0.05)。治疗后,两组患者的IL-6、IFN-γ水平均降低,且研究组低于对照组,差异具有统计学意义(P<0.05)。结论胸腺五肽联合四联抗结核方案治疗耐药性肺结核病效果显著,可有效改善患者的肺功能、免疫功能以及血清炎症因子水平,值得临床实践应用。
Objective To investigate the clinical effect of thymopentin combined with quadruple antituberculosis regimen in the treatment of drug-resistant tuberculosis.Methods A total of 60 cases of drug-resistant tuberculosis patients admitted from September 2016 to September 2019 were selected as the research objects and divided into control group and study group according to different treatment methods,with 30 cases in each group.The control group was treated with quadruple antituberculosis regimen,and the study group was treated with thymopentin injection on the basis of the control group.The therapeutic effects,pulmonary function indexes,immune function indexes and serum inflammatory factors levels of the two groups were compared.Results The total effective rate of treatment of the study group was 93.33%,which was significantly higher than 70.00%of the control group,and the difference was statistically significant(P<0.05).After treatment,FEV1%and FEV1/FVC of the two groups increased,and those in the study group were higher than the control group,and the differences were statistically significant(P<0.05).After treatment,the CD3+,CD4+and CD4+/CD8+in the two groups increased,and those in the study group were higher than the control group,and the differences were statistically significant(P<0.05).After treatment,IL-6 and IFN-γlevels of both groups decreased,and those in the study group were lower than the control group,and the differences were statistically significant(P<0.05).Conclusion Thymopentin combined with quadruple antituberculosis regimen has a significant effect on drug-resistant tuberculosis,it can effectively improve the pulmonary function,immune function and serum inflammatory factors levels,which is worthy of clinical practice and application.
作者
毛峰立
崔艳莹
周春燕
MAO Fengli;CUI Yanying;ZHOU Chunyan(Infectious Disease Control Department,Xi'an Huyi District Center for Disease Control and Prevention,Xi'an 710300;Internal Medicine Department,Xi'an Huyi District Hospital of Traditional Chinese Medicine,Xi'an 710300;Internal Medicine Department,Shaanxi Sengong Hospital,Xi'an 710300,China)
出处
《临床医学研究与实践》
2020年第27期45-47,共3页
Clinical Research and Practice
关键词
胸腺五肽
四联抗结核方案
耐药性肺结核病
肺功能
免疫功能
thymopentin
quadruple antituberculosis regimen
drug-resistant tuberculosis
pulmonary function
immune function
